MOv18 is in phase 1 clinical testing with early data demonstrating safety and signs of biological activity in patients with ovarian cancer.8 9 77 We showed that SF-25 IgE could restrict the growth of tumor lesions in the lung of mice when administered with human immune effector cells. Here, IGHE is linked to ovarian carcinoma.